Insulin Receptor antibody (N-Term)

Catalog No. ABIN1881461

Product Details anti-Insulin Receptor Antibody

Target: Insulin Receptor (INSR)

Binding Specificity: AA 826-854, N-Term

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This Insulin Receptor antibody is un-conjugated

Application: Western Blotting (WB)

Predicted Reactivity: M, Rat

Purification: This antibody is purified through a protein A column, followed by peptide affinity purification.

Immunogen: This INSR antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 826-854 amino acids from the N-terminal region of human INSR.

Clone: RB42484

Isotype: Ig Fraction

Application Details

Application Notes: WB: 1:1000

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Expiry Date: 6 months

Target Details for Insulin Receptor

Target: Insulin Receptor (INSR)

Alternative Name: INSR (INSR Products)

Synonyms: CD220 antibody, HHF5 antibody, 4932439J01Rik antibody, D630014A15Rik antibody, IR antibody, IR-A antibody, IR-B antibody, 18402 antibody, CG18402 antibody, DIHR antibody, DILR antibody, DIR antibody, DIRH antibody, DIRbeta antibody, DInR antibody, DInr antibody, Dir-a antibody, Dir-b antibody, Dmel\\CG18402 antibody, INR antibody, INS antibody, Inr antibody, Inr-alpha antibody, Inr-beta antibody, InsR antibody, dINR antibody, dIR antibody, dIRH antibody, dInR antibody, dInr antibody, dInsR antibody, dinr antibody, dir antibody, er10 antibody, inr antibody, insulin/insulin-like growth factor receptor antibody, l(3)05545 antibody, l(3)93Dj antibody, l(3)er10 antibody, lnR antibody, ir-A antibody, CTK-1 antibody, ir antibody, INSR antibody, NV14476 antibody, cd220 antibody, hhf5 antibody, insulin receptor antibody, Insulin-like receptor antibody, insulin receptor L homeolog antibody, INSR antibody, Insr antibody, InR antibody, LOC100122567 antibody, LOC100451802 antibody, insr.L antibody

Background: Receptor tyrosine kinase which mediates the pleiotropic actions of insulin. Binding of insulin leads to phosphorylation of several intracellular substrates, including, insulin receptor substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling intermediates. Each of these phosphorylated proteins serve as docking proteins for other signaling proteins that contain Src-homology-2 domains (SH2 domain) that specifically recognize different phosphotyrosines residues, including the p85 regulatory subunit of PI3K and SHP2. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway, which is responsible for most of the metabolic actions of insulin, and the Ras-MAPK pathway, which regulates expression of some genes and cooperates with the PI3K pathway to control cell growth and differentiation. Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to the activation of PI3K and the generation of phosphatidylinositol-(3, 4, 5)-triphosphate (PIP3), a lipid second messenger, which activates several PIP3-dependent serine/threonine kinases, such as PDPK1 and subsequently AKT/PKB. The net effect of this pathway is to produce a translocation of the glucose transporter SLC2A4/GLUT4 from cytoplasmic vesicles to the cell membrane to facilitate glucose transport. Moreover, upon insulin stimulation, activated AKT/PKB is responsible for: anti-apoptotic effect of insulin by inducing phosphorylation of BAD, regulates the expression of gluconeogenic and lipogenic enzymes by controlling the activity of the winged helix or forkhead (FOX) class of transcription factors. Another pathway regulated by PI3K-AKT/PKB activation is mTORC1 signaling pathway which regulates cell growth and metabolism and integrates signals from insulin. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 thereby activating mTORC1 pathway. The Ras/RAF/MAP2K/MAPK pathway is mainly involved in mediating cell growth, survival and cellular differentiation of insulin. Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers the activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to binding insulin, the insulin receptor can bind insulin-like growth factors (IGFI and IGFII). Isoform Short has a higher affinity for IGFII binding. When present in a hybrid receptor with IGF1R, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.

Molecular Weight: 156333

NCBI Accession: NP_000199, NP_001073285

UniProt: P06213

Pathways: NF-kappaB Signaling, RTK Signaling, AMPK Signaling, Carbohydrate Homeostasis, Regulation of Cell Size, Regulation of Carbohydrate Metabolic Process, Growth Factor Binding, Negative Regulation of Transporter Activity